A major objective of this proposal is to determine the molecular mechanisms underlying the enhanced neurotoxicity of MPTP in aged rodents (C57B1/6 mice). This objective is directly related to our long-term goal of using neurotoxins to determine the molecular mechanisms underlying the process of neuronal degeneration in Parkinson's disease. A second objective is to determine if the neuropathological changes in the nervous system of the old mouse more closely resemble those seen in Parkinson's disease than those observed in younger animals given MPTP. Success in these studies could lead to a greater understanding of the disease and why it affects the aging nervous system. In turn, new treatment and possibly even preventative strategies, as well as a much more accessible animal model for the disease might be realized. Specifically, we will study the various factors which might influence the biodisposition of MPTP and its major metabolite, MPP+, in animals of different ages to see which of these are responsible for the enhanced effects of MPTP in aged animals. Secondly, we plan to delineate the morphological features of MPTP-induced neurotoxicity in old mice, and compare them with those seen in Parkinson's disease, and in MPTP-induced parkinsonism in primates. Methodology to be used will involve the introduction of MPTP, MPP+ and other neurotoxins in animals of different ages. These compounds will be administered both systemically and directly to the CNS, either alone or in combination with pharmacological agents which block or exacerbate toxicity. Similar in-vitro studies with these agents will also be performed. Analytical techniques to be used for the identification and quantitation of neurotransmitters, MPTP, MPP+, other toxins, drugs and metabolites will include high pressure liquid chromatography (with spectrophotometric and electrochemical detection); gas chromatography/mass spectroscopy; radiometric techniques (liquid scintillation counting); and spectrophotometric techniques. In addition, standard histological techniques will be employed to assess the morphological features of MPTP in aged rodents.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG007348-03
Application #
3118381
Study Section
Neurology A Study Section (NEUA)
Project Start
1988-04-01
Project End
1991-03-31
Budget Start
1990-04-01
Budget End
1991-03-31
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
California Institute for Medical Research
Department
Type
DUNS #
076321173
City
San Jose
State
CA
Country
United States
Zip Code
95128
Irwin, I; Delanney, L; Chan, P et al. (1997) Nigrostriatal monoamine oxidase A and B in aging squirrel monkeys and C57BL/6 mice. Neurobiol Aging 18:235-41
Finnegan, K T; Irwin, I; Delanney, L E et al. (1995) Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B. J Pharmacol Exp Ther 273:716-20
Irwin, I; DeLanney, L E; McNeill, T et al. (1994) Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 3:251-65
Irwin, I; DeLanney, L E; Langston, J W (1993) MPTP and aging. Studies in the C57BL/6 mouse. Adv Neurol 60:197-206
Irwin, I; Finnegan, K T; Delanney, L E et al. (1992) The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res 572:224-31
Finnegan, K T; Skratt, J J; Irwin, I et al. (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 184:119-26
Langston, J W (1989) Current theories on the cause of Parkinson's disease. J Neurol Neurosurg Psychiatry Suppl:13-7
Irwin, I; DeLanney, L E; Di Monte, D et al. (1989) The biodisposition of MPP+ in mouse brain. Neurosci Lett 101:83-8
Finnegan, K T; DeLanney, L E; Irwin, I et al. (1989) The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age. Brain Res 496:251-6
Di Monte, D; Irwin, I; Kupsch, A et al. (1989) Diethyldithiocarbamate and disulfiram inhibit MPP+ and dopamine uptake by striatal synaptosomes. Eur J Pharmacol 166:23-9